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Calcium citrate ameliorates the progression of chronic renal
injury.
Background. Metabolic acidosis is a consequence of chronic
renal failure and it may produce bone demineralization, muscle
proteolysis, and progression of chronic renal failure. The aim of
this study was to evaluate the effects of correction of metabolic
acidosis with calcium citrate in an experimental model of renal
mass ablation.
Methods. Wistar rats were subjected to 5/6 nephrectomy
and were randomly assigned to one of 4 groups: nontreated
(NFX); treated with calcium citrate (1.45 g/100 g feed) (NFX-
CIT); treated with captopril (500 mg/L water) (NFX-CAP); or
treated with both (NFX-CAP-CIT) during 1, 10, or 20 weeks.
Body weight, systolic blood pressure, proteinuria, arterial bicar-
bonate concentration, urine citrate excretion, plasma calcium,
and inulin clearance were measured. Histologic glomerular and
tubulointerstitial damage scores were measured at 1, 10, and
20 weeks, and glomerular and tubular proliferating cell nu-
clear antigen (PCNA)-positive cells, a−smooth muscle actin,
and desmin staining were studied by immunohistochemistry at
1 and 10 weeks.
Results. The treated groups showed significantly less
glomerular and tubulointerstitial cellular proliferation in the
first week (P < 0.05), less glomerular cell transdifferentiation
and higher plasma bicarbonate at 10 weeks (P < 0.05), as well as
diminished histologic glomerular and tubulointerstitial damage
scores at 20 weeks (P < 0.05). Inulin clearances were higher (P <
0.05), and urine protein excretion rates were lower (P < 0.05)
than in the NFX non-treated group, but arterial blood pressure
was not significantly different in the NFX-CIT group.
Conclusion. Calcium citrate slows the progression of chronic
renal injury in the 5/6 NFX model. It improves metabolic aci-
dosis and diminishes cell proliferation and transdifferentiation
without changes in systolic blood pressure.
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The progression to end-stage renal failure is inde-
pendent of the initial pathogenetic mechanism [1]. The
common destructive mechanism that leads any chronic
renal disease to glomerulosclerosis and chronic tubuloin-
terstitial damage has been extensively investigated [2–7],
and the experimental model most widely used is the 5/6
nephrectomy [4].
Metabolic acidosis is a common consequence of
chronic renal failure [8, 9] that results from an inadequate
ammonium excretion and decreased tubular bicarbonate
reabsorption [10]. It has severe consequences because it
enhances renal bone disease (renal osteodystrophy) [11]
and activates muscle proteolysis [12]. There is evidence
that acidosis diminishes glomerular filtration rate [13].
Ammonia production by remnant nephrons is increased
after partial nephrectomy [14], and it probably produces
renal damage. Logan [15] found in normal rat kidney cells
that urea stimulates DNA synthesis, and Ling et al [16]
observed that ammonia produces mesangial and tubu-
lar cell hypertrophy. Nath et al [17] have demonstrated
that proteinuria (after 5/6 nephrectomy in rats) decreased
when renal ammoniagenesis is reduced by supplementa-
tion with sodium bicarbonate. They suggested that am-
monia stimulates the alternative complement pathway so
it produces tubulointerstitial inflammation and renal in-
jury with altered tubular function [18, 19], and it is also a
stimulus to renal growth [19]. Throssell et al [20] were not
able to demonstrate the benefits of sodium bicarbonate
supplementation. Acidotic rats with normal renal func-
tion developed proteinuria and renal hypertrophy and
hyperplasia. Throssell et al [21] considered that filtered
proteins are not metabolized by tubular cells. Together
these data suggest that metabolic acidosis may aggravate
progression of chronic renal failure.
In previous experiments we administered NaHCO3
during 20 weeks to 5/6 nephrectomized Wistar rats, and
they developed severe arterial hypertension and nei-
ther improved glomerular filtration rate nor diminished
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histologic lesions compared with nontreated nephrec-
tomized groups (unpublished results).
Citrate, an alkalinizing agent, is reabsorbed in the re-
nal proximal tubule by a sodium-coupled transporter,
the Na+/dicarboxylate cotransporter, with a broad sub-
strate specificity for Kreb’s cycle intermediates [22, 23].
Tanner et al have recently demonstrated [24–26] that cit-
rate salts improve renal function in rats with polycystic
kidney disease, mainly by its alkalinizing effect. Toblli et
al [27] also demonstrated a beneficial effect of potassium
citrate supplementation in uric acid nephropathy. We
have observed that calcium citrate supplementation also
attenuates tubulointerstitial damage in the rat model of
obstructive nephropathy [abstract; Gadola et al, J Am
Soc Nephrol 12:703A, 2001]. Calcium citrate would be a
safer citrate salt to use in a chronic renal failure model to
avoid the risks of sodium or potassium overload. As far
as we know there are no reports on calcium citrate effects
on the ablation model of progression of renal failure.
The aims of this study were to evaluate the effects on
chronic renal failure progression and its mechanisms of
an early and prolonged alkalinization with calcium citrate
in the 5/6 nephrectomy model, with no changes in the diet
sodium content or systemic haemodynamics.
METHODS
Male Wistar rats weighing 256 ± 74 g were divided into
5 groups. One of the groups was sham operated (SHAM)
(N = 18). Five-sixths renal ablation by right nephrectomy,
and ablation of two thirds of the left kidney, under anes-
thesia with intraperitoneal thiopental, was performed in
72 rats. Previously, systolic blood pressure in awake rats
was measured by tail optical plethysmography (custom-
made device). Urine was collected during 24 hours in
a metabolic cage (Nalgene; Nalge Nunc International,
Rochester, NY, USA) and urinary protein excretion was
determined. All rats were placed in individual cages with
natural light and controlled room temperature, and they
were handled according to Principles of Laboratory Ani-
mal Care (National Institutes of Health, 1985). They had
free access to water and standard diet with 24% protein.
Immediately after nephrectomy (NFX), the rats were
randomly assigned to 4 groups (18 rats each): (1) non-
treated (NFX); (2) captopril (NFX-CAP) (Squibb, Darm-
stadt, Germany) was administered 500 mg/L in drinking
water; (3) calcium citrate (NFX-CIT) (Mission Pharma-
cal, San Antonio, TX, USA) was administered 1.45 g/
100 g feed; and (4) calcium citrate plus captopril (NFX-
CAP-CIT). The 5 groups (sham and the 4 NFX groups)
were divided into three subgroups according to observa-
tion time: 1 week, 10 weeks, and 20 weeks (6 rats each).
At 10 and 20 weeks body weight, systolic blood pres-
sure, 24-hour urinary protein excretion, and arterial bi-
carbonate (obtained from aorta under anesthesia with
thiopental) were measured. At 20 weeks, 24-hour urine
citrate excretion, inulin clearance, and plasma calcium
were also measured.
Analytical methods
Urinary protein excretion was assayed by the turbidi-
metric method with sulfosalicylic acid. Plasma calcium
was measured by O-cresolphthalein automated assay
(Roche Diagnostics, Mannheim, Germany). Inulin con-
centrations in plasma and urine were measured by col-
orimetric anthrone method (Shimadzu UV400A; Kyoto,
Japan). Arterial bicarbonate was measured with a blood
gas analyzer (ABL 700; Radiometer, Copenhagen, Den-
mark). Urine citrate was determined by the enzymatic
citrate lyase method (Nielsen’s method).
Inulin clearance
Rats were anesthetized with intraperitoneal sodium
thiopental (35 mg/kg body weight) and they were placed
on a temperature-regulated table. After tracheostomy,
PE-50 catheters were inserted into the left and right inter-
nal jugular veins for infusion of normal saline and inulin
(10%; Sigma Chemical Co., St. Louis, MO, USA). A PE-
50 catheter was inserted in the left femoral artery to mea-
sure mean arterial pressure (Nikon Kohden Life Scope
8, Tokyo, Japan) and blood sampling. A PE-10 catheter
was inserted into the left ureter for collection of urine (or
both ureters in the sham-operated group). Inulin was ad-
ministered by a continuous flow of 1.2 mL/hour via infu-
sion pump (Harvard Apparatus, Hollinston, MA, USA).
Clearance measurements were carried out in two inter-
vals of 20 minutes each, after allowing 50 minutes for
equilibration of plasma inulin concentration.
Immunohistochemistry
Sections of methyl Carnoy’s fixed kidney tissues were
processed by indirect immunodetection technique with
Biotin streptavidin amplified detection system (Bio-
Genex, San Ramon, CA, USA) using three primary an-
tibodies (Biogenex): mouse monoclonal antibodies to
(1) proliferating nuclear cell antigen (PCNA) (dilution
1:200), as a marker of cell proliferation; to (2) desmin
(dilution 1:80); and to (3) a−smooth muscle actin (dilu-
tion 1:100) as markers of myofibroblast transformation
[28–30].
Negative controls consisted of substitution of the
primary antibody with equivalent concentrations of a
normal rabbit immunoglobulin (Ig)G (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Mean score per
biopsy was calculated as follows: glomerular PCNA as
the mean number of proliferating (positive) cells in 15
glomeruli (cells/glomerular cross section); PCNA tubu-
lar/interstitial score was obtained as the mean number of
proliferating cells in 20 fields, 0.1 mm2 each (cells/fields).
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Table 1. Functional measurements on sham-operated rats and 5/6-nephrectomized rats treated with captopril, calcium citrate, or
captopril-calcium citrate
SHAM NFX NFX-CAP NFX-CIT NFX-CAP-CIT
Body weight 20 w g 467 ± 56 318 ± 60b 402 ± 25 334 ± 47 387 ± 35
SBP 10 w mm Hg 106 ± 12 102 ± 18 105 ± 15 117 ± 18 102 ± 4
SBP 20 w mm Hg 111 ± 13 137 ± 20b 99 ± 9a 129 ± 19 103 ± 9a
Prot ur 10 w mg/day 9 ± 4 69 ± 6b 13 ± 8a 23 ± 10a 32 ± 14a
Prot ur 20 w mg/day 15 ± 7 152 ± 71b 27 ± 22a 28 ± 19a 46 ± 21a
Art bic 10 w mEq/L 25.5 ± 1.6 17.3 ± 2.4b 23.8 ± 3.6a 25 ± 3.5a 25.3 ± 2.8a
Art bic 20 w mEq/L 20.5 ± 3.3 16.3 ± 3.7 20.5 ± 1.6 20.7 ± 2.3 20.3 ± 1.6
Ca 20 w mg/dL 7.6 ± 0.5 7.4 ± 0.9 8.4 ± 0.8a 8.3 ± 0.3a 9.1 ± 0.4a
Ur citrate 20 w mg/day 25 ± 7 7 ± 5b 5 ± 3 17 ± 8 18 ± 12a
Inulin Cl 20 w lL/min/100 g 447 ± 142 22 ± 11b 87 ± 47a 92 ± 29a 103 ± 60a
Abbreviations are: SBP, systolic blood pressure; Prot ur, proteinuria; Art bic, arterial bicarbonate concentration; Ca, plasma calcium concentration; Ur citrate, urine
citrate excretion; Inulin Cl, inulin clearance; w, weeks; SHAM, sham-operated group; NFX, 5/6 nephrectomized group; NFX-CAP, treated with captopril group; NFX-
CIT, treated with calcium citrate group; NFX-CAP-CIT, treated with captopril and calcium citrate group. N = 6 in all the subgroups. All data are mean ± SD.
aP < 0.05 vs. NFX.
bP < 0.05 vs. SHAM.
For the evaluation of desmin and a−smooth muscle
actin, each glomerulus and tubulointerstitial grid field
was graded semiquantitatively according to the extent of
the staining from 0 (absent) to 4 (more than 75% in the
glomerular tuft) or 5 (more than 75% of tubulointersti-
tial field). Mean scores of 15 glomeruli and 20 fields were
calculated in each kidney.
Morphologic techniques
All remnant kidneys were fixed with Bouin’s solu-
tion for histologic study and those from the 1 and
10 weeks subgroups were divided in halves, and one half
was fixed with Carnoy to perform immunohistochem-
istry. Glomerulosclerosis (GS) index was assessed in 100
glomeruli per animal, according to El Nahas et al [31]
on periodic-acid Schiff (PAS)-stained paraffin sections at
a magnification of ×400. Glomerulosclerosis was graded
from 0 to 4 by a semiquantitative score: grade ∗0 nor-
mal, ∗1 mesangial expansion/sclerosis involving less than
25% of the tuft, ∗2 moderate GS (25%-50%), ∗3 severe
GS (50%-75%), and grade ∗4 (diffuse GS involving more
than 75% of the glomerular tuft). Glomerulosclerosis in-
dex for each animal was calculated as a mean value of
all glomerular scores obtained. Tubulointerstitial indexes
were determined using a semiquantitative scoring system
according to Veniant et al [32] on PAS-stained sections at
a magnification of ×100. Ten fields per kidney were ex-
amined and lesions were graded from 0 to 3 according to
the area with tubulointerstitial changes (tubular atrophy,
casts, interstitial inflammation, and fibrosis). The score
index in each rat was expressed as a mean value of all
scores obtained.
All the histologic analyses were performed by an ob-
server unaware of the treatment received by each group.
STATISTICS
Values are reported as mean ± SD. Groups were com-
pared by one-way analysis of variance (ANOVA) test,
followed by post hoc pair-wise comparisons using
Student-Newman–Keuls test, or linear regression and
correlation test. P values < 0.05 were considered statisti-
cally significant.
RESULTS
Values for body weight, systolic blood pressure, urinary
protein excretion, arterial bicarbonate, plasma calcium,
urine citrate, and inulin clearance are shown in Table 1.
The NFX group has less final weight, significantly higher
systolic blood pressure (P < 0.05), and urinary protein
excretion (P < 0.05) versus the sham-operated group. Ar-
terial bicarbonate and inulin clearance were lower than
the sham-operated group (P < 0.05).
The group treated with calcium citrate alone (NFX-
CIT) for 20 weeks had significantly lower proteinuria
(28 ± 18 mg/day) than the NFX group (152 ± 71 mg/day)
(P < 0.05), but no difference in systolic blood pressure
was observed. The groups treated with captopril alone
or with captopril and calcium citrate showed significantly
lower blood pressure and urinary protein excretion ver-
sus the control group (P < 0.05).
Plasma calcium concentration was higher in the groups
treated with calcium citrate alone (8.3 ± 0.3 mg/dL) or
with captopril (9.1 ± 0.4 mg/dL) than that in the NFX
group (7.4 ± 0.9 mg/dL) (P < 0.05). At 10 weeks the arte-
rial bicarbonate was significantly lower in the NFX group
(17.3 ± 2.4 mEq/L) versus the sham-operated (25.5 ±
1.6 mEq/L) and the treated groups (NFX-CIT 25 ±
3.5 mEq/L, NFX-CAP 23.8 ± 3.6 mEq/L, and NFX-CAP-
CIT 25.3 ± 2.8 mEq/L) (P < 0.05). At 20 weeks the ar-
terial bicarbonate was low in all groups (because it was
obtained after the performance of the inulin clearance),
and it was lowest in the NFX group (NS). Urine citrate
excretion was lower in the NFX group (7 ± 5 mg/day) ver-
sus the sham-operated (25 ± 7 mg/day) (P < 0.05), and
higher in the NFX-CIT (NS) and NFX-CAP-CIT (P <
0.05) groups.
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Table 2. Immunohistochemistry
SHAM NFX NFX-CAP NFX-CIT NFX-CAP-CIT
PCNA glom 1 w 0.35 ± 0.25 0.92 ± 0.6b 0.17 ± 0.25a 0.22 ± 0.21a 0.4 ± 0.3a
PCNA glom 10 w 0.13 ± 0.06 1.58 ± 0.98b 0.08 ± 0.18a 0.19 ± 0.22a 0.07 ± 0.13a
PCNA tub 1 w 1.8 ± 0.8 15.1 ± 14.6b 3.98 ± 1.11a 4.83 ± 2.29a 2.36 ± 1.36a
PCNA tub 10 w 0.27 ± 0.11 1.57 ± 0.16b 0.38 ± 0.23a 1.48 ± 1 1.07 ± 0.63
PCNA int 1 w 1.0 ± 0.93 3.27 ± 2.3b 0.89 ± 0.23a 1.23 ± 0.57a 0.87 ± 0.25a
PCNA int 10 w 0.11 ± 0.04 0.66 ± 0.5 0.21 ± 0.16 0.59 ± 0.33 0.4 ± 0.35
Desmin glom 1 w 0.18 ± 0.18 0.43 ± 0.15 0.19 ± 0.2 0.23 ± 0.29 0.3 ± 0.18
Desmin glom 10 w 0.13 ± 0.15 0.85 ± 0.34b 0.48 ± 0.41a 0.28 ± 0.21a 0.14 ± 0.13a
Desmin T-int 1 w 0.23 ± 0.19 0.67 ± 0.67 0.29 ± 0.31 0.2 ± 0.26 0.14 ± 0.1
Desmin T-int 10 w 0.19 ± 0.08 0.34 ± 0.19 0.18 ± 0.15 0.27 ± 0.18 0.09 ± 0.07
a–SMA glom 1 w 0 ± 0 0.33 ± 0.5 0 ± 0 0.14 ± 0.11 0 ± 0
a–SMA glom 10 w 0 ± 0 1.62 ± 1.17b 0.65 ± 0.88a 0.13 ± 0.13a 0.12 ± 0.14a
a–SMA T-int 1 w 0.03 ± 0.05 0 ± 0 0 ± 0 0.45 ± 0.46 0 ± 0
a–SMA T-int 10 w 0 ± 0 1.34 ± 1.6 0.83 ± 0.65 0.25 ± 0.42 0.06 ± 0.13
Abbreviations are: PCNA, proliferating cell nuclear antigen; glom, glomerular, tub, tubular; T-int, tubulointerstitial, a–SMA, a–smooth muscle actin; w, weeks.
N = 6 in all the subgroups. All data are mean ± SD.
aP < 0.05 vs. NFX.
bP < 0.05 vs. SHAM.
The inulin clearances were significantly higher in the
groups treated with calcium citrate (NFX-CIT) (92 ±
29 uL/min/100 g), with captopril (NFX-CAP) (87 ± 47 uL/
min/100 g), and both (NFX-CAP-CIT) (103 ± 60 uL/
min/100 g) than in the NFX group (22 ± 11 uL/min/100 g)
(P < 0.05). There were no significant differences in urine
protein excretion, arterial bicarbonate, inulin clearance
between NFX-CIT, NFX-CAP, and NFX-CAP-CIT.
Thus, calcium citrate diminished proteinuria and en-
hanced plasma calcium concentration, arterial bicarbon-
ate, and inulin clearances in spite of persistent high sys-
tolic blood pressure.
Immunohistochemistry
The immunohistochemistry data at 1 and 10 weeks are
shown in Table 2 and Figure 1A-F. At 1 and 10 weeks
glomerular and tubulointerstitial cell proliferation
(PCNA-positive cells) are significantly lower in the sham-
operated or the treated groups versus the NFX group
(P < 0.05). At 10 weeks, desmin and a–smooth muscle
actin staining were significantly more extensive at the
glomerular tufts in the NFX group than in the sham-
operated or the treated groups (P < 0.05).
Renal morphology
The histologic glomerular and tubulointerstitial scores
are shown in Table 3 and Figure 1G-H. At 20 weeks the
groups treated with calcium citrate and/or captopril had
significantly less glomerular and tubulointerstitial dam-
age than the NFX nontreated group (P < 0.05). The urine
protein excretion had a significantly positive correlation
with tubulointerstitial damage (r2 = 0.6, P < 0.05) (Fig. 2),
and a weak correlation with glomerulosclerosis (r2 = 0.25,
P < 0.05).
DISCUSSION
In the present study, calcium citrate supplementation
to rats with 5/6 nephrectomy improved arterial plasma
bicarbonate, diminished proteinuria, and enhanced in-
ulin clearance, and it ameliorated glomerular and tubu-
lointerstitial damage. Calcium citrate also diminished
glomerular and tubular cell proliferation and glomeru-
lar cell transdifferentiation (myofibroblast transforma-
tion) at early stages as shown by PCNA, desmin, and
a−smooth muscle actin staining.
It is well known that captopril also diminishes protein-
uria, enhances inulin clearance [4, 7, 33], and, in this study,
also elevates plasma bicarbonate, probably as it improves
renal function. Although calcium citrate has similar ef-
fects on proteinuria, plasma bicarbonate, and inulin clear-
ance, there was no additive effect of calcium citrate and
captopril.
The observed effects of calcium citrate may be pro-
duced by different mechanisms: correction of metabolic
acidosis, changes in intracellular pH, calcium, and/or cit-
rate intracellular concentrations.
Citrate effects
Citrate is selectively taken up by the kidneys, and as
its metabolism produces bicarbonate, may be a good way
to target bases to the kidney cells [25]. Wright et al [34]
and Hering-Smith et al [35] have demonstrated on cul-
tured cells with acute and chronic acidosis that a low
extravesicular pH stimulated Na-dependent citrate trans-
port in renal brush border membrane vesicles. During
metabolic acidosis citrate reabsorption and cytosol con-
centration would be increased. Tanner and Tanner [25]
have recently demonstrated that different citrate salts
improved renal function in rats with polycystic kidney
disease probably due to its alkalinizing effect, although
the exact mechanism is still unknown [26].
Citrate synthase activity is elevated in the remnant
glomeruli. Experimental models with reduced glomeru-
lar citrate synthase activity are protected from remnant
nephropathy [36]. It can be hypothesized that changes in





Fig. 1. Histologic sections of kidney from
5/6 nephrectomized Wistar rat. Immunohis-
tochemistry staining. Representative results
are shown. (A) Glomerular and tubuloin-
terstitial proliferating cell nuclear antigen
(PCNA) immunostaining in rats 1 week af-
ter 5/6 nephrectomy (NFX). Sections were
counterstained with eosin (original magnifi-
cation ×200), and (B) from a calcium citrate–
treated animal (NFX-CIT). Sections were
counterstained with eosin (original magnifi-
cation ×200). (C) Immunohistochemical de-
tection of a−smooth muscle actin in rats
10 weeks after 5/6 nephrectomy (original
magnification ×400), and (D) from a cal-
cium citrate–treated animal (NFX-CIT) that
shows positive staining only in arterioles
(original magnification ×400). (E) Immuno-
histochemical detection of desmin in rats
10 weeks after 5/6 nephrectomy (original mag-
nification ×400), and (F) from a calcium
citrate–treated animal (NFX-CIT) that shows
positive staining only in arterioles (original
magnification ×400). (G) Periodic-acid Schiff
(PAS) staining in rats 20 weeks after nephrec-
tomy showing glomerulosclerosis, tubular at-
rophy, and interstitial infiltration (original
magnification ×200), and (H) from a calcium
citrate–treated animal (NFX-CIT) (original
magnification ×200).
intracellular citrate concentration may also have direct
actions.
Calcium effects
Calcium carbonate improved progressive renal dam-
age in deoxycorticosterone acetate (DOCA)-salt model
in rats mainly by its phosphate binding action [37], but
acid-base status was not determined, and carbonate may
also have a mild alkalinizing effect. Hatton and McCar-
ron [38] postulated that calcium has antihypertensive ac-
tions mediated by many different possible mechanisms. In
the present study the NFX-CIT group has persistent sys-
temic hypertension, although some calcium effect upon
microcirculation cannot be ruled out. Plasma calcium lev-
els are significantly higher in the NFX-CIT group and
also in the NFX-CAP group (Table 1). Probably as cap-
topril improves renal function, phosphorus and calcium
metabolism is improved. Simultaneous supplementation
of calcium and citrate may have complementary benefi-
cial effects in a chronic renal failure model.
Metabolic acidosis-glomerular filtration rate
It has been postulated that acidosis is a “uremic toxin”
[39] because it enhances protein degradation, stimulates
the ubiquitin-proteasome proteolytic complex, produces
muscle wasting and malnutrition [40], and inhibits nor-
mal bone formation. Furthermore, Farber et al [13]
have demonstrated that metabolic acidosis depressed
glomerular filtration rate and effective renal plasma
flow, perhaps through a hormone-mediated mechanism
[41]. Protein catabolic end products (urea and ammonia)
[12] may also contribute to renal damage [12, 14–19].
Gadola et al: Calcium citrate ameliorates chronic renal injury 1229
Table 3. Glomerulosclerosis and tubulointerstitial damage score
SHAM NFX NFX-CAP NFX-CIT NFX-CAP-CIT
Glom score
1 week 0.27 ± 0.2 0.42 ± 0.4 0.15 ± 0.13 0.18 ± 0.1 0.24 ± 0.1
10 week 0.18 ± 0.1 0.83 ± 0.54 0.24 ± 0.1 0.37 ± 0.34 0.27 ± 0.2
20 week 0.17 ± 0.09 0.82 ± 0.28b 0.39 ± 0.13a 0.44 ± 0.43a 0.12 ± 0.07a
T-int score
1 week 0.03 ± 0 0 ± 0 0.14 ± 0.2 0.1 ± 0.2 0 ± 0
10 week 0 ± 0 0.1 ± 0.13 0.08 ± 0.15 0.04 ± 0.05 0.25 ± 0.29
20 week 0.4 ± 0.21 1.18 ± 0.56b 0.36 ± 0.1a 0.52 ± 0.27a 0.48 ± 0.25a
See Table 1 for abbreviations. Glom score, glomerulosclerosis damage score; T-int score, tubulointerstitial damage score. N = 6 in all the subgroups. All data are
mean ± SD.
aP < 0.05 vs. NFX.
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Fig. 2. Correlation between proteinuria and tubulointerstitial score at
20 weeks. (R2 = 0.6, P < 0.05).
Enhanced renal ammoniagenesis observed in the re-
duced renal mass model may determine renal hypertro-
phy [16, 42]. In the present study plasma bicarbonate
and glomerular filtration rate are significantly elevated in
the NFX-CIT group, probably due to citrate alkalinizing
effect.
Glomerular and tubulointerstitial damage
Floege et al [28] and Kliem et al [29] observed that
glomerular and tubulointerstitial cell proliferation be-
gan within 5–7 days of renal ablation and peaked at
2 weeks, and the expression of myofibroblast markers
such as a−smooth muscle actin and desmin were also
increased (phenotypic changes) [43]. The cellular pro-
liferation and transdifferentiation in this model may be
mediated by several mechanisms. The tubulointerstitial
proliferation was found to correlate with caloric intake,
angiotensin II, several growth factors, and ammonia
[44]. In the present study calcium citrate administration
(Table 2) significantly diminished glomerular cell pro-
liferation and transdifferentiation, and the correction
of metabolic acidosis may have participated in this ef-
fect because plasma bicarbonate was higher at 10 weeks
in the NFX-CIT versus NFX group. The higher in-
ulin clearance in the NFX-CIT group may be explained
by the diminished glomerular cell proliferation and
transdifferentiation.
Proteinuria
Urinary protein excretion diminished in the group
treated with calcium citrate probably as a consequence
of the observed decreased glomerular damage (Table 3).
Systolic blood pressure did not change in this group
(Table 1), suggesting that this effect may be independent
of a systemic hemodynamic action.
It has been demonstrated that acidosis may also pro-
duce proteinuria of tubular origin [45, 46]. Chronic
acidosis increased ammonia production and may have
contributed to the tubulointerstitial inflammation by
complement activation [17]. It has been observed that
NH4Cl produces swelling of lysosomes in proximal tubu-
lar cells in culture [47] and a reduction in lysosomal activ-
ity [48]. Calcium citrate, as an alkalinizing agent, would
diminish NH4+ concentration in the proximal tubular
cells and cortical interstitium, improve intracellular pro-
tein metabolism, and as a consequence, diminish tubu-
lointerstitial damage (Table 3) and a possible tubular
component of proteinuria. The exact composition of pro-
teinuria was not determined in the present study, but we
can hypothesize that both a glomerular and tubular com-
ponent would be diminished by the treatment.
CONCLUSION
The administration of calcium citrate after 5/6 nephrec-
tomy: (1) ameliorates metabolic acidosis and diminishes
proteinuria without changes in systolic blood pressure;
(2) diminishes cell proliferation and transdifferentiation
at early stages and glomerular and tubulointerstitial dam-
age at 20 weeks; and (3) improves glomerular filtration
rate.
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